These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 12137603

  • 1. [The effects of angiotensin-converting enzyme inhibitor on IgA nephropathy and the influencing factors].
    Shi X, Chen X, Liu S, Zhuang Y, Zhang Y.
    Zhonghua Nei Ke Za Zhi; 2002 Jun; 41(6):399-403. PubMed ID: 12137603
    [Abstract] [Full Text] [Related]

  • 2. Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
    Bazzi C, Rizza V, Paparella M, Casellato D, Napodano P, Olivieri G, D'Amico G.
    J Nephrol; 2009 Jun; 22(3):387-96. PubMed ID: 19557716
    [Abstract] [Full Text] [Related]

  • 3. Validation of some pathophysiological mechanisms of the CKD progression theory and outcome prediction in IgA nephropathy.
    Bazzi C, Rizza V, Casellato D, Stivali G, Rachele G, Napodano P, Olivieri G, Gallieni M, D'Amico G.
    J Nephrol; 2012 Jun; 25(5):810-8. PubMed ID: 22252844
    [Abstract] [Full Text] [Related]

  • 4. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up.
    Kanno Y, Okada H, Saruta T, Suzuki H.
    Clin Nephrol; 2000 Nov; 54(5):360-5. PubMed ID: 11105796
    [Abstract] [Full Text] [Related]

  • 5. ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis.
    Woo KT, Lau YK, Wong KS, Chiang GS.
    Kidney Int; 2000 Dec; 58(6):2485-91. PubMed ID: 11115082
    [Abstract] [Full Text] [Related]

  • 6. A clinicopathological study of IgA nephropathy in renal transplant recipients: beneficial effect of angiotensin-converting enzyme inhibitor.
    Oka K, Imai E, Moriyama T, Akagi Y, Ando A, Hori M, Okuyama A, Toki K, Kyo M, Kokado Y, Takahara S.
    Nephrol Dial Transplant; 2000 May; 15(5):689-95. PubMed ID: 10809812
    [Abstract] [Full Text] [Related]

  • 7. The effectiveness of steroid therapy for patients with advanced IgA nephropathy and impaired renal function.
    Moriyama T, Honda K, Nitta K, Yumura W, Nihei H.
    Clin Exp Nephrol; 2004 Sep; 8(3):237-42. PubMed ID: 15480901
    [Abstract] [Full Text] [Related]

  • 8. Increased Serum IgA in Children with IgA Nephropathy, Severity of Kidney Biopsy Findings and Long-Term Outcomes.
    Mizerska-Wasiak M, Małdyk J, Pańczyk-Tomaszewska M, Turczyn A, Cichoń-Kawa K, Rybi-Szumińska A, Wasilewska A, Firszt-Adamczyk A, Stankiewicz R, Bieniaś B, Zajączkowska M, Gadomska-Prokop K, Grenda R, Miklaszewska M, Pietrzyk J, Pukajło-Marczyk, Zwolińska D, Szczepańska M, Demkow U, Roszkowska-Blaim M.
    Adv Exp Med Biol; 2015 Sep; 873():79-86. PubMed ID: 26269025
    [Abstract] [Full Text] [Related]

  • 9. Significance of clinical and morphological prognostic risk factors in IgA nephropathy: follow-up study of comparison patient groups with and without renoprotection.
    Riispere Ž, Kuudeberg A, Seppet E, Sepp K, Ilmoja M, Luman M, Kõlvald K, Auerbach A, Ots-Rosenberg M.
    BMC Nephrol; 2017 Mar 14; 18(1):89. PubMed ID: 28292274
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy.
    Cruzado JM, Poveda R, Ibernón M, Díaz M, Fulladosa X, Carrera M, Torras J, Bestard O, Navarro I, Ballarín J, Romero R, Grinyó JM.
    Nephrol Dial Transplant; 2011 Nov 14; 26(11):3596-602. PubMed ID: 21393611
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Significance of vascular lesions in IgA nephropathy and their influencing factors, a study of 1,005 cases].
    Wu J, Chen XM, Shi SZ.
    Zhonghua Yi Xue Za Zhi; 2003 Feb 25; 83(4):289-93. PubMed ID: 12812644
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of severe Henoch-Schönlein and immunoglobulin A nephritis. A single center experience.
    Edström Halling S, Söderberg MP, Berg UB.
    Pediatr Nephrol; 2009 Jan 25; 24(1):91-7. PubMed ID: 18931859
    [Abstract] [Full Text] [Related]

  • 19. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.
    Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Node K.
    Am J Hypertens; 2007 Nov 25; 20(11):1195-201. PubMed ID: 17954367
    [Abstract] [Full Text] [Related]

  • 20. Treatment of IgA nephropathy with angiotensin converting enzyme inhibitors: design of a prospective randomized multicenter trial.
    Coppo R, Chiesa M, Peruzzi L, Amore A.
    J Nephrol; 2001 Nov 25; 14(6):447-52. PubMed ID: 11783600
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.